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ABSTRACT  
Urine is a potential source of diagnostic biomarkers for detection of diseases, and is a very attractive means of 
non-invasive biospecimen collection. Nonetheless, proteomic measurement in urine is very challenging because 
diagnostic biomarkers exist in very low concentration (usually below the sensitivity of common immunoassays) 
and may be subject to rapid degradation. Hydrogel nanoparticles functionalized with Cibacron Blue F3G-A 
(CB) have been applied to address these challenges for urine biomarker measurement. We chose one of 
the most difficult low abundance, but medically relevant, hormones in the urine: human growth hormone 
(hGH). The normal range of hGH in serum is 1 to 10 ng/mL but the urine concentration is suspected to be a 
thousand times less, well below the detection limit (50 pg/mL) of sensitive clinical hGH immunoassays. We 
demonstrate that CB particles can capture, preserve and concentrate hGH in urine at physiological salt and urea 
concentrations, so that hGH can be measured in the linear range of a clinical immunometric assay. Recombinant 
and cadaveric hGH were captured from synthetic and human urine, concentrated and measured with an 
Immulite chemiluminescent immunoassay. Values of hGH less than 0.05 ng/mL (the Immulite detection limit) 
were concentrated to 2 ng/mL, with a urine volume of 1 mL. Dose response studies using 10 mL of urine 
demonstrated that the concentration of hGH in the particle eluate was linearly dependent on the concentration 
of hGH in the starting solution, and that all hGH was removed from solution. Thus if the starting urine volume 
is 100 mL, the detection limit will be 0.1 pg/mL. Urine from a healthy donor whose serum hGH concentration 
was 1.34 ng/mL was studied in order detect endogenous hGH. Starting from a volume of 33 mL, the particle 
eluate had an hGH concentration of 58 pg/mL, giving an estimated initial concentration of hGH in urine of 0.175 
pg/mL. The nanotechnology described here appears to have the desired precision, accuracy and sensitivity to 
support large scale clinical studies of urine hGH levels.
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Introduction
Urine is a biological fluid produced by the kidney 
through a process of blood filtration, reabsorption 
and tubular secretion. Although it is predominantly 
composed of waste products, it may contain a vast 
amount of biological information useful for diagnostic 
purposes and is a mirror of physiopathological 
urogenital and systemic conditions [1].
Urine is an ideal biological fluid for clinical 
a n a l y s i s  b e c a u s e  t h e  c o l l e c t i o n  i s  s i m p l e , 
economic, and non-invasive, and large quantities 
of sample are available.  For these reasons it 
has been proposed as an alternative to blood 
collection (venipuncture), if not as a diagnostic 
tool, at least as a screening test used to determine 
which subjects should undergo serum analysis. 
Nevertheless, the very low concentration of many 
molecules of interest in urine, and the presence of 
different interfering substances, have hampered 
the development of urine-based diagnostics tests, 
as well as the discovery of novel clinically useful 
biomarkers. The recent application of modern 
proteomic technologies and approaches to urine 
have led to the discovery of hundreds of proteins 
as new potential biomarkers of disease [2, 3]. 
The existence of these potential urine disease 
biomarkers has paradoxically highlighted the 
weakness of urine as a diagnostic fl uid: (1) the total 
protein concentration of urine is highly variable 
from hour to hour depending on the hydration 
state and the kidney function; (2) the size range 
and composition of proteins normally entering the 
urine is a function of glomerular filtration and is 
not simply proportional to the blood concentration 
of a given biomarker; (3) diagnostic biomarkers 
may exist in very low concentrations in the urine 
(the concentration of many blood biomarkers 
may be one hundred to one thousand times less 
than that in the blood, such that the marker is 
undetectable by a conventional clinical assay); (4) 
urine biomarkers may be highly labile and subject 
to degradation. Thus there is a great clinical need 
to create new tools that will selectively concentrate 
and preserve low abundance peptides and proteins 
in the urine [2 4].
Nanomedicine, the application of nanotechnology 
to the medical field [5], offers a potential means 
of overcoming the above drawbacks of urine. 
Nanoparticles provide a new medium for the 
selective concentration and uptake of  urine 
biomarkers. Many classes of nanoparticles (such 
as quantum dots, gold nanoparticles, magnetic 
nanoparticles, and hydrogels) have been proposed to 
be applicable in diagnosis, monitoring, and treatment 
of disease [6]. Among known nanoparticles, hydrogel 
particles offer a simple means to capture, concentrate 
and preserve urinary proteins of interest. 
Hydrogel particles are submicron spheres 
obtained via polymerization of water soluble 
monomers, and consist of swollen three-dimensional 
networked structures in which water is the major 
component.  The size of the particles can change in 
response to a variety of stimuli, such as temperature, 
pH, ionic strength, light and electric fields [7 13]. 
Because of their physicochemical properties and 
their open structure, hydrogel particles offer an 
effective means to encapsulate target analytes in 
solution.  Because of their swelling and de-swelling 
properties in response to mild modifications of 
the solution and their ability to be functionalized 
with different chemical moieties, they have been 
extensively investigated as targeted drug delivery 
systems [14, 15].
Recently we demonstrated the ability of poly(N-
isopropylacrylamide) (NIPAm) based hydrogel 
particles to rapidly capture and concentrate low 
molecular weight (LMW) and low abundance 
proteins from a complex protein solution such as 
serum, and preserve the captured analytes from 
degradation [16]. Their particle porosity is ideal 
for size selection of proteins, especially the LMW 
proteins and peptides that are likely to be passed 
into the urine. A variety of chemical ligands that 
act as affinity baits have been incorporated in the 
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NIPAm based particles (e.g., acrylic acid, allylamine, 
p-vinylphenylboronic acid [17],  N-acryoyl-m-
aminophenylboronic acid [18], cyclodextrins, and 
triazinyl dyes). The baits can be designed to sequester 
specific classes of proteins or metabolites, thereby 
increasing the affi nity between the particles and the 
analytes.
In this study we have applied this new class of 
harvesting nanoparticles to urine samples. In order 
to give proof of concept, we chose one of the most 
difficult low abundance, but medically relevant, 
hormones present in urine: human growth hormone 
(hGH). In fact hGH is currently undetectable in 
urine when measured by the most sensitive clinical 
assay used for measuring hGH in serum [19, 20]. 
Human growth hormone is a peptide hormone 
of 191 amino acids secreted by somatotroph cells 
of the pituitary gland in a pulsatile pattern under 
hypothalamic control [21, 22]. Its secretion is 
influenced by several physiological and patho-
physiological conditions such as gender, age, sleep, 
fever, physical exercise, nutritional state and other 
metabolic factors. As a result, hGH levels in blood 
fluctuate widely. In humans, hGH levels reach 
50 100 ng/mL at peak and fall below 0.03 ng/mL 
at nadir [19]. Blood contains multiple hGH isoforms 
(22, 20, and 17 kDa), with the 22 kDa form being 
the most abundant [23, 24]. The principal metabolic 
clearance of hGH proceeds through glomerular 
fi ltration, reabsorption and degradation in proximal 
tubular cells. This clearance process is very effi cient, 
with only a very minute amount of filtrated hGH 
(<0.01%) reaching the final urine volume [19]. 
Several previous studies have shown that given an 
intact renal function hGH concentration in urine, 
although much lower than in serum (between one 
hundred to one thousand times less than that in 
blood in the low pg/mL range [25, 26]) refl ects its 
physiological secretion. 
Determination of hGH levels is a key tool for the 
clinical management of hGH secretion disorders: 
childhood and adulthood insuffi ciency or overproduction. 
Accurate, universally valid and convenient hGH 
measurements in urine are highly desirable but, 
for many reasons, this goal remains elusive [19, 
20]. Many efforts have been made to detect hGH in 
urine, both for clinical and anti-doping purposes 
using different classes of immunologic assays (e.g., 
NordiTest U-hGH assay and Nichols Institute 
Chemoluminescence uGH immunoassay) [27, 28] 
but the very low concentration of the hormone 
in urine, complexity of the assays, and high 
costs involved have hindered clinical urine test 
development. Assessment of nonphysiological levels 
of hGH still relies on time consuming, expensive 
and potentially hazardous tests, such as repetitive 
blood measurement or dynamic (stimulating 
or suppressive) tests. In order to overcome the 
drawbacks of current methods of hGH testing in 
urine, we synthesized hydrogel NIPAm nanoparticles 
incorporating a Cibacron Blue dye bait. Cibacron 
Blue F3G-A (CB) is a monochlorotriazinyl textile dye, 
containing an antraquinone chromophore. It is widely 
used as a ligand, coupled to numerous matrices, in 
affinity chromatography because of its well known 
ability to interact with proteins [29, 30]. Recently the 
ability of CB to interact with recombinant hGH has 
been demonstrated [31, 32].
In this study we demonstrate that this novel 
nanotechnology is  able to capture,  preserve 
and concentrate hGH in urine so that hGH can 
be determined in the linear range of a clinical 
immunometric assay (Immulite-Siemens Medical 
Solution Diagnostic), as depicted in Fig. 1. These 
particles capture all of the hGH in the bulk fluid 
of the urine, and since the protein is then collected 
in a small volume the concentration of hGH is 
signifi cantly increased.
The harvesting particles we describe are not 
specific to the case study we chose, hGH, but also 
have the capability to capture, concentrate and protect 
from degradation other classes of low molecular 
weight medically relevant protein biomarkers in 
urine.  In order to prove the non-specificity of the 
harvesting particles, capture of interleukin 8 (IL-8) 
was investigated. IL-8 is a chemokine involved in 
proinflammatory and proangiogenic processes, the 
increased concentration of which in the urine of 
non-Hodgkin’s Lymphoma patients was recently 
reported [33].
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1. Experimental 
1.1 Materials and reagents
Cibacron Blue F3G-A dye (CB), N-isopropylacrylamide 
(NIPAm), N-N’-methylenebis(acrylamide) (BIS), 
allylamine (AA) and potassium persulfate (KPS) 
were purchased from Sigma-Aldrich, Inc, USA. 
Recombinant hGH 22 kDa Humatrope was purchased 
from Lilly, International Standard for hGH (Cadaveric 
hGH),  was purchased from NIBSC, UK, and 
synthetic urine (Surine, Negative Control for urine 
testing) was purchased from Dyna-Tek Industries. 
18% Tris-Glycine gel and Tris-Glycine SDS running 
buffer were purchased from Invitrogen Corporation, 
USA. GH Sample Diluent was purchased from 
Siemens Medical Solution Diagnostic. Urine for the 
experiments was collected from healthy donors with 
IRB approved protocol.
1.2 Synthesis and characterization 
of hydrogel nanoparticles 
NIPAm/AA particles were prepared 
containing specific percentages of 
AA with respect to the total monomer 
(5% or 10%). NIPAm (0.89 g, 7.83 mmol) 
and BIS (0.042 g, 0.27 mmol) were 
dissolved in 30 mL of H2O and 
then passed through a 0.2 m filter 
nylon membrane. The solution was 
purged with nitrogen for 15 min at 
room temperature with a medium 
stirring rate before AA (0.026 g, 
0.45 mmol for 5% loaded particles 
and 0.051 g, 0.90 mmol for 10% AA 
loaded particles) was added.  The 
solution was purged with nitrogen 
for another 15 min and then heated 
to 75 °C [34].  KPS (0.0070 g, 0.025 
m mol)  i n  1.0  m L  of  H 2O  wa s 
added to the solution to initiate 
polymerization. The reaction was 
maintained at 75°C  under nitrogen 
for  3  hours.  The reac t ion was 
subsequently allowed to cool to room temperature 
and stirred overnight. The reaction mixture was then 
transferred to 2 mL microcentrifuge tubes and the 
particles harvested and washed via centrifugation 
(Eppendorf 5415R centrifuge). After centrifuging 
the particle suspension for 20 min at 23 °C and 16 100 
relative centrifugal force (rcf), the supernatant from each 
tube was decanted and the particles were redispersed 
in 1.0 mL H2O. This concentration/redispersion process 
was repeated for a total of fi ve washes. 
To obtain NIPAm/CB particles, CB (0.38 g, 
0.45 mmol) was dissolved in 5 mL of 0.1 mol/L 
aqueous sodium carbonate. The NIPAm/AA particle 
suspension (5 mL volume) was purged with nitrogen 
for 15 min with a medium stirring rate in a 100 mL 
three-neck round-bottom flask, after which solid 
sodium carbonate (0.053 g, 0.50 mmol) was added to 
the suspension. The suspension was then stirred at 
room temperature under nitrogen for about 1 min.
The CB solution was then added to the NIPAm/
AA particle suspension, and the combined reaction 
Figure 1 Amplifi cation strategy for immunological detection of human growth hormone 
(hGH) in urine. Particles are mixed with urine, subsequently capture hGH, and are separated 
via centrifugation.  Elution of hGH from particles is performed with an acetonitrile (ACN)-
NH4OH buffer.  Immunoassay is performed on hGH eluted from the particles
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mixture was then stirred at room temperature under 
nitrogen for 48 h. The resulting NIPAm/CB particles 
were harvested and washed using centrifugation 
as described earlier in the preparation of NIPAm/
AA particles. Dye loading was determined via 
spectrophotometry (Thermo Spectronic 20+). A 
calibration curve was constructed using CB stock 
solutions of known concentrations. The supernatants 
from the entire concentration/redispersion process 
were combined, and their absorbance at a wavelength 
of 608 nm was determined. The CB concentration of 
the combined supernatants was estimated using the 
calibration curve. 
The synthesis of NIPAm/acrylic acid (AAc) 
particles has been described previously [16].  
NIPAm/beta-cyclodextrin (β-CD) particles were 
obtained as follows: NIPAm/N-(hydroxymethylacry
lamide) (HMA) particles were fi rst prepared: NIPAm 
(0.92 g) and BIS (0.03 g) were dissolved in 30 mL 
of H2O and then filtered with a 0.2 μm filter nylon 
membrane. HMA (0.008 g) was added to the reaction 
flask, and the solution was purged with nitrogen 
for 30 min. The solution was then heated to 70 °C 
and maintained at this temperature for 30 min. KPS 
(0.007 g) in 1 mL H2O was then added to the reaction 
flask to initiate polymerization. The reaction was 
maintained at 70 °C for 3 h. The reaction was then 
removed from the heat and allowed to cool to room 
temperature overnight, with the resulting NIPAm/
HMA particles being harvested and washed using 
centrifugation as described earlier in the preparation 
of NIPAm/AA particles. Beta-cyclodextrin (0.12 g) 
was dissolved in 1% HCl solution, and 5 mL of the 
NIPAm/HMA particle suspension was introduced 
into the reaction flask. The resulting suspension 
was then purged with nitrogen for 15 min at room 
temperature. After 15 min, the suspension was heated 
to 80 °C and maintained at that temperature 
for 1 h under nitrogen with a medium stirring 
rate. The resulting NIPAm/β-CD particles were 
then harvested and washed using centrifugation as 
described earlier in the preparation of NIPAm/AA 
particles. Particle concentration was assessed by 
weighing the lyophilized particles obtained from a 
known volume of the particle suspension.
The dependence of particle size on temperature 
was determined via photon correlation spectroscopy 
(submicron particle size analyzer, Beckman Coulter). 
The measurement of particle diameter was performed 
using water as diluent (refractive index (RI)= 
1.333, diluent viscosity=0.890 cP). The test angle 
was 90°. Average values were calculated for three 
measurements using a 200 s integration time, and the 
solutions were allowed to thermally equilibrate for 
10 min before each set of measurements. Measured 
values were then converted to particle sizes via 
the Stokes Einstein relationship [35]. Atomic force 
microscopy (AFM) images were acquired on particles 
using an NSCRIPTOR™ DPN® System (NanoInk). 
Particle suspensions (1 mg/mL) were deposited on 
freshly cleaved mica under a humidifi ed atmosphere 
for 15 min and dried under nitrogen before 
measurement. Images were acquired under AC mode 
using a silicon tip with a typical resonance frequency 
of 300 kHz and a radius smaller than 10 nm. 
  
1.3   Particle incubation with analyte solutions
Aliquots of particles were incubated with 1 mL 
of buffers, Surine or human urine for 1 h at room 
temperature under slow rotation. After incubation, 
the particles were centrifuged (7 min, 25 °C, 16 100 
rcf), the supernatant was saved and the particles 
were washed three times by resuspending the pellets 
in 1 mL of water and centrifuging (7 min, 25 °C , 
16 100 rcf). The particles were then directly loaded on 
the gel or incubated with elution buffers. Incubations 
with 10 mL of Surine were performed with 50 
mL centrifuge tubes (Nalgene) and particles were 
separated from urine by centrifugation (45 min, 25 °C, 
18 000 revolutions per minute (rpm)) and washed as 
previously described.
1.4   Elution of hGH from particles
The washed pellet of particles was incubated for 15 
min at room temperature or for one hour at 38 °C with 
proper amounts of elution. buffers. After incubation, 
the particles were centrifuged (7 min, 25 °C, 16 100 
rcf) and the eluate was saved. The elution step was 
repeated twice and the eluates were pooled together.
1.5   SDS-PAGE and silver staining
Sodium dodecyl  sulfate  polyacrylamide gel 
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electrophoresis (SDS-PAGE) was performed using 
18% Tris-Glycine gel in the presence of Tris-Glycine 
SDS running Buffer on a Novex X-Cell IITM Mini-
Cell (Invitrogen Corporation, USA), at 200 V. The 
gels were stained by silver staining.
1.6   Immunometric assay 
The concentration of hGH eluted from particles was 
measured using the Immulite 1000 Growth Hormone 
System (Siemens Medical Solution Diagnostic). 
Eluates were diluted in GH Sample Diluent, and 
assayed according to the manufacturer’s instructions.
2. Results and discussion
2.1   Synthesis and characterization of hydrogel NIPAm/
Cibacron Blue F3GA particles 
The hydrogel particles utilized in this study were 
obtained by incorporating Cibacron Blue F3G-A dye 
in N-isopropylacrylamide (NIPAm)/allylamine (AA) 
particles. NIPAm/AA particles were synthesized 
via precipitation polymerization under a nitrogen 
atmosphere using BIS as cross linker. AA was added 
Figure 2 Chemical reactions for the synthesis of particles: (a) allylamine functionalized particles are 
created; (b) Cibacron Blue F3G-A dye is covalently incorporated into the particles via the amino group
Figure 3 Characterization of Cibacron Blue F3G-A loaded particles: 
(a) atomic force microscopy (AFM) image showing size homogeneity; 
(b) picture of 2 mL vials of NIPAm/CB and NIPAm/AA particles
by copolymerization to the NIPAm particles in order 
to have an amino group that can bind to the triazine 
ring of the dye via HCl elimination (Fig. 2). The 
estimated dye loading was respectively 50% and 56% 
for the 5% and the 10% AA particles. 
As shown in the AFM images (Fig. 3(a)) the 
particles are homogenous in size with a diameter 
of about 800 nm. A picture of 2 mL vials of NIPAm/CB 
and NIPAm/AA particles is shown in Fig. 3(b). 
Light scattering analysis was conducted in the 
（a）
（b）
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The concentration of particles was assessed by 
weighing the lyophilized particles (5.7 μg/μL).
Hydrogels are jelly-like materials composed of a 
network of polymeric chains in which the degree of 
porosity can be tuned by changing the percentage 
of the cross-linker N-N’-methylenebis(acrylamide) 
(BIS).  This polymeric network acts as a sieve, 
allowing NIPAm/CB particles to perform size 
exclusion chromatography in solution. The degree 
of homogeneity in the distribution of pore sizes in 
the particles can be assessed by the sharpness of 
the molecular weight cut-off. In order to evaluate 
the size sieving properties of NIPAm/CB particles 
and define the molecular weight cut-off we used 
a mixed solution of proteins of known molecular 
weight.  Aprotinin (MW 6.5 kDa, Sigma-Aldrich), 
lysozyme (MW 14.4 kDa, Sigma-Aldrich), bovine 
serum albumin, BSA (MW 66 kDa, Fisher Scientifi c), 
ovalbumin (MW 45 kDa, Sigma-Aldrich), hGH 
(MW 22 kDa, Humatrope Lilly), and insulin growth 
factor binding protein 7, IGFBP7 (MW 31 KDa, 
Preprotech) were dissolved in Surine at pH 5 at a 
concentration of 0.1 μg/μL, and incubated with 
100 μL (570 μg) of NIPAm/CB particles for 30 min 
at room temperature. The suspension was then 
centrifuged and the particles washed with water. 
Particles and supernatant were analyzed by SDS-
Figure 4 Photon correlation spectroscopy analysis of dependence 
of particle size on temperature: (a) plot of average values of light 
scattering measurements of particle diameter at different temperatures. 
Hydrogel particles are thermoresponsive; (b) histograms showing the 
amplitude of the particle size distribution at each temperature
（a）
（b）
temperature range 20 to 50 °C; as reported in Fig. 4(a) 
the diameter of particles showed an inverse relation 
with temperature, decreasing from the maximum 
average value of 884.9 nm ± 8.5 nm at 20 °C to a 
minimum of 255.9 nm ± 5.4 nm measured at 50 °C, 
consistent with the typical temperature dependent 
behavior of hydrogel nanoparticles. Histograms 
based on intensities of particle size distribution for 
each temperature run are reported in Fig. 4(b).  
Figure 5 Evaluation of size exclusion properties of NIPAm/CB 
particles by SDS-PAGE. Particles were incubated with a mixture of 
proteins with a molecular weight range between 66 and 6.5 kDa, 
dissolved in Surine. Lane 1 protein mixture; Lane 2 supernatant (Out), 
Lane 3 particle content (In). Only proteins with a molecular weight 
lower than 45 KDa were trapped by the particles; ovalbumin and BSA 
were completely excluded
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PAGE (Fig. 5). We observed that only proteins with 
molecular weight less than 45 kDa were captured 
by the particles (Lane 3) and the molecular weight 
cut-off was estimated between 45 and 31 kDa. The 
sharpness of the molecular weight cut-off suggests 
that the distribution of pore size in the particles was 
very homogeneous. 
2.2   Harvesting of hGH by NIPAm/Cibacron Blue 
F3GA particles
In order to select the best performing particles to 
harvest hGH from solution, we compared four 
classes of hydrogel NIPAm nanoparticles containing 
different baits (CB (5% and 10% AA), AA, AAc 
and β-CD). Recombinant hGH was dissolved at 
a concentration of 0.2 mg/mL in sodium citrate 
buffer (pH 5, 50 mmol/L) and aliquots of 50 μL 
were incubated with 50 μL of each different class 
of particles for 1 h at room temperature. After 
incubation, the supernatant was saved and the 
particles were washed. Supernatants and particles 
were subjected to SDS PAGE analysis and silver 
stained (Fig. 6). NIPAm/CB particles proved to be the 
most effi cient in harvesting hGH from solution (Lanes 
3, 5), leaving undetectable concentrations of the 
hormone in the bulk supernatant, as demonstrated by 
the corresponding blank lanes on the gel (Lanes 2, 4). 
Only a small amount of hormone was sequestered by 
β-CD,  NIPAm/AA, and NIPAm/AAc bait particles 
(Lanes 6 11), indicative of a weak affi nity of the baits 
for the analyte. The NIPAm/AAc particles carry a 
negative charge at pH greater than 3.5 that leads 
to stronger electrostatic interactions with cationic 
species, whereas the human hGH (pI 5.27) under 
the experimental conditions described is expected 
to be almost neutral. Moreover at the physiological 
pH of urine (pH 4 10), the protein is expected to be 
mostly negatively charged, thus explaining why the 
NIPAm/AAc particles were not effective for hGH 
harvesting. The NIPAm/AA particles are positively 
charged but their effi ciency in capturing the hormone 
is not as high as that of the NIPAm/CB particles, 
because the specific interaction with the target is 
conferred primarily by the bait. It has been widely 
shown in the literature that β-CD has high affi nities 
for small molecules such as cholesterol, steroids, 
and DOPA [36–38], and it therefore acts as a good 
negative control for hGH uptake. 
2.3 Harvesting and concentration of hGH by 
NIPAm/CB particles in urine models
Human urine contains a multitude of organic and 
inorganic compounds, and is characterized by high 
levels of salt concentration and pH between 4 and 
10. Urea is the most abundant nitrogenous metabolic 
waste (comprising about 95% of the nitrogen content 
of urine). Salts and urea can potentially infl uence the 
behavior of a harvesting nanoparticle and interfere 
with the interactions between CB and hGH. In 
order to evaluate hGH harvesting performance in 
conditions as similar as possible to physiological 
urine, we studied the effects of urea, salts and 
different pH levels on the hGH harvesting effi ciency 
of the particles.
Samples of hGH (0.01 mg/mL) were spiked in the 
following solutions: urea (0.7 mg/mL, physiological 
concentration), KCl (6.0 mg/mL, comparable to the 
total amount of salts in urine) and different buffered 
solutions with pH values ranging from 4 to 10 (50 
Figure 6 SDS-PAGE analysis of particles carrying different baits and 
their ability to harvest hGH. Lane 1 hGH control; Lane 2 Cibacron 
Blue 5% loaded particle supernatant (Out); Lane 3 Cibacron Blue 
5% loaded particle content (In); Lane 4 Cibacron Blue 10% loaded 
particle supernatant (Out); Lane 5 Cibacron Blue 10% loaded particle 
content (In); Lane 6 allylamine particle supernatant (Out); Lane 7 
allylamine particle content (In); Lane 8 beta-cyclodextrin loaded 
particle supernatant (Out); Lane 9 beta-cyclodextrin loaded particle 
content (In); Lane 10 acrylic acid particle supernatant (Out); Lane 
11 acrylic acid particle content (In). Cibacron Blue 5% and 10% 
had the best affinity for hGH of all the particles tested and both 
completely depleted the supernatant and achieved a high degree of 
concentration of the hGH
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and supernatants were analyzed by SDS-
PAGE analysis. As shown in Fig. 7(a), 
physiological concentrations of urea and 
salts did not hinder the ability of particles to 
capture hGH (Lanes 17 20). The harvesting 
was optimal in the pH range from 4 to 
6 (Lanes 3 9). Under these conditions, 
particles were capable of increasing hGH 
concentration from an undetectable level 
(Lane 2) to a clearly visible band (Lanes 
4, 7, 9). Increasing the solution pH caused 
a decrease in harvesting efficiency. These 
data suggest that acidic conditions favor the 
molecular interaction between the dye and 
the hGH.
We confirmed our results by spiking 
hGH in Surine which is a medium routinely 
used as a negative control for urine tests. 
Aliquots of hGH (0.01 mg/mL) were 
dissolved in Surine at pH values of 4, 5, 6.7, 
and 8.  The pH of Surine was 6.7 at 22 °C, and 
therefore the pH was adjusted as necessary 
by adding appropriate amounts of HCl 
or NaOH. Aliquots of 100 μL (570 μg) of 
particles were incubated with 1 mL of 
Surine. Harvesting of hGH was evaluated 
by SDS PAGE analysis. Sequestration 
extent and concentrations of hGH were 
estimated for each pH value (Fig. 7(b)); 
pH 5 was assessed as the optimal uptake 
condition (Lanes 5, 6).  
Taken together, these results suggested 
that acidic conditions were more favorable 
for hGH uptake than basic conditions, 
and therefore we decided to carry out the 
incubations at pH 5, which is representative 
of physiological conditions, and then to 
increase the pH as a means of eluting hGH 
from the particles. 
mmol/L sodium citrate buffer titrated to pH 4, 5 and 
6; 50 mmol/L Tris HCl buffer titrated to pH 7 and 8; 
50 mmol/L carbonate-bicarbonate buffer titrated to 
pH 10). One milliliter of each solution was incubated 
with 100 μL (570 μg) of NIPAm/CB particles. 
Particles were centrifuged and washed and particles 
Figure 7 SDS PAGE analysis of particles incubated with solutions of different 
pH values, in the presence of urea and salts. (a) Study of the effect of pH, urea 
and KCl on particle uptake of hGH. Lane 1 hGH control; Lane 2 0.01 mg/mL hGH 
solution at pH 4; Lane 3 NIPAm/CB particle supernatant at pH 4 (Out); Lane 4 
NIPAm/CB particle content at pH 4 (In); Lane 5 0.01 mg/mL hGH solution at pH 5; 
Lane 6  NIPAm/CB particle supernatant at pH 5 (Out); Lane 7 NIPAm/CB particle 
content at pH 5 (In); Lane 8 NIPAm/CB particle supernatant at pH 6 (Out); Lane 9 
NIPAm/CB particle content at pH 6 (In); Lane 10 NIPAm/CB particle supernatant 
at pH 7 (Out); Lane 11 NIPAm/CB particle content at pH 7 (In); Lane 12 NIPAm/CB 
particle supernatant at pH 8 (Out); Lane 13 NIPAm/CB particle content at pH 8 
(In); Lane 14 0.01 mg/mL hGH solution at pH 10; Lane 15 NIPAm/CB particle 
supernatant at pH 10 (Out); Lane 16 NIPAm/CB particle content at pH 10 (In); Lane 
17 NIPAm/CB particle supernatant in presence of urea (Out); Lane 18 NIPAm/CB 
particle content in presence of urea (In); Lane 19 NIPAm/CB particle supernatant 
in presence of KCl (Out); Lane 20 NIPAm/CB particle content in presence of KCl 
(In). Uptake of hGH is higher at lower pH and it is not hindered by the presence 
of urea or KCl.  (b) SDS PAGE analysis of NIPAm/CB particles incubated with hGH 
diluted in synthetic urine (Surine) at different pH values. Lane 1 hGH control; Lane 
2 0.01 mg/mL hGH solution in Surine; Lane 3 NIPAm/CB particle supernatant 
at pH 4 (Out); Lane 4 NIPAm/CB particle content at pH 4 (In); Lane 5 NIPAm/CB 
particle supernatant at pH 5 (Out); Lane 6 NIPAm/CB particle content at pH 5 (In); 
Lane 7  NIPAm/CB particle supernatant at pH 6.7 (Out); Lane 8 NIPAm/CB particle 
content at pH 6.7 (In); Lane 9  NIPAm/CB particle supernatant at pH 8 (Out); Lane 
10 NIPAm/CB particle content at pH 8 (In). Particles successfully sequestered hGH 
from solution, and the effi ciency was higher at lower pH
2.4 Time course studies
In order to understand the kinetics  of  hGH 
sequestration by CB particles, an uptake time course 
study was performed.  Aliquots of 1 mL of 0.01 
mg/mL hGH in Surine at pH 5 were incubated with 
（a）
（b）
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100 μL (570 μg) of CB particles and the incubation 
was allowed to proceed for 1, 5, 20, 40, and 60 min. 
Particles were separated by centrifugation and 
washed. Particles and supernatants were subjected 
to SDS PAGE analysis (Fig. 8(a)). Capture of hGH 
was a very fast process; after only one minute the 
majority of hGH was detectable inside the particles 
(Lane 3). Moreover, in order to test the capability of 
the nanoparticles to preserve captured hGH from 
degradation over time, we performed a time course 
experiment to assess the stability of the sequestered 
hGH over a period of 48 h. CB particles (100 μL, 570 μg) 
were incubated with 1 mL of 0.01 mg/mL hGH in 
Surine for 1, 4, 24, and 48 h at room temperature, 
as described above. SDS PAGE analysis showed no 
detectable loss of hGH harvesting, and full hGH 
preservation at each incubation time (Fig. 8(b)).
2.5 Sequestration by CB particles of the different 
isoforms of cadaveric hGH spiked in Surine
Since endogenous, naturally produced hGH exists as 
a series of different size isoforms, but recombinant 
hGH consists of only the 22 kDa form, it was 
necessary to assess whether CB particles sequestered 
all three main isoforms of hGH (22, 20, and 17 kDa). 
The cadaveric WHO international standard for 
hGH (which contains all the natural isoforms) was 
spiked in Surine at a concentration of 0.01 mg/mL 
and incubated with 100 μL (570 μg) of CB particles. 
Particles were separated from Surine and washed as 
previously described. Particles and supernatant were 
subjected to SDS-PAGE analysis (Fig. 9). As shown 
in Lane 3, particles sequestered and concentrated all 
three isoforms (22, 20, and 17 kDa) so that the less 
abundant forms became detectable by SDS-PAGE. 
The starting solution prior to particle sequestration 
was loaded in Lane 1 and the only visible band 
corresponds to the 22 kDa form.Figure 8 SDS PAGE analysis of time studies. (a) Uptake time course. 
Lane 1 hGH control; Lane 2 NIPAm/CB particle supernatant after 
1 min incubation (Out); Lane 3 NIPAm/CB particle content after 1 
min incubation (In); Lane 4 NIPAm/CB particle supernatant after 5 
min incubation (Out); Lane 5 NIPAm/CB particle content after 5 min 
incubation (In); Lane 6 NIPAm/CB particle supernatant after 20 min 
incubation (Out); Lane 7 NIPAm/CB particle content after 20 min 
incubation (In); Lane 8 NIPAm/CB particle supernatant after 40 min 
incubation (Out); Lane 9 NIPAm/CB particle content after 40 min 
incubation (In); Lane 10 NIPAm/CB particle supernatant after 60 min 
incubation (Out); Lane 11 NIPAm/CB particle content after 60 min 
incubation (In). The sequestration process was very fast, with the 
majority of hGH being captured by particles after one minute.  (b) 
Preservation time course. Lane 1 hGH control; Lane 2 NIPAm/CB 
particle supernatant after 1 h (Out); Lane 3 NIPAm/CB particle content 
after 1 h incubation (In); Lane 4 NIPAm/CB particle supernatant 
after 4 h incubation (Out); Lane 5 NIPAm/CB particle content after 
4 h incubation (In); Lane 6 NIPAm/CB particle supernatant after 
24 h incubation (Out); Lane 7 NIPAm/CB particle content after 24 
h incubation (In); Lane 8 NIPAm/CB particle supernatant after 48 
h incubation (Out); Lane 9 NIPAm/CB particle content after 48 h 
incubation (In). Once captured by particles, hGH remains stable up to 
at least 48 h
Figure 9 SDS PAGE analysis of cadaveric hGH spiked in Surine and 
incubated with particles.  Lane 1 0.01 mg/mL cadaveric hGH solution 
in Surine; Lane 2 NIPAm/CB particle supernatant (Out); Lane 3 NIPAm/
CB particle content (In). Particles sequestered all the three major 
isoforms of hGH (22, 20, and 17 kDa) and increased the concentration 
of the minor isoforms, so that they could be detected by silver staining
（a）
（b）
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2.6 Harvesting and concentration of IL-8 by 
NIPAm/CB particles in Surine
CB dye is an affi nity ligand for a vast class of proteins: 
in fact it is well known for its affi nity for nucleotide 
binding proteins [30], and various mechanisms of 
interaction between CB dye and proteins have been 
hypothesized, such as electrostatic, hydrophobic, 
hydrogen bonding and charge transfer interactions 
[29]. Therefore, NIPAm/CB particles can capture and 
concentrate a wide class of low molecular weight 
proteins in solution. The ability of NIPAm/CB 
nanoparticles to capture and concentrate interleukin 
8 (IL 8), another potential biomarker of disease, 
was tested in Surine. IL 8 is a member of the class 
of CXC chemokines and acts as a proinflammatory 
and proangiogenic cytokine associated with tumor 
progression, prognosis and survival in several types 
of cancer [39–41]. Recently, serum and urine levels 
in non-Hodgkin’s lymphoma (NHL) patients have 
been investigated and IL-8 levels were found to be 
significantly higher in patients with NHL than in 
healthy individuals [33].
IL 8 (8.4 kDa, AbD Serotec) was spiked in 1 mL 
of Surine at a concentration of 0.004 mg/mL and the 
solution was incubated with 100 μL (570 μg) of NIPAm/
CB particles. Particles were centrifuged and washed 
as previously described. Particles and supernatant 
were then analyzed by SDS-PAGE and silver staining 
(Fig. 10). It was found that NIPAm/CB particles 
captured and concentrated IL-8 in solution (Lane 3) and 
completely removed IL-8 from the supernatant (Lane 2). 
of 1 mL of 0.01 mg/mL hGH in Surine at pH 5 were 
incubated with 100 μL (570 μg) of CB particles and 
washed as previously described. The particle pellets 
were subsequently incubated for 15 min with the 
following elution buffers: 50 mmol/L Tris HCl 
pH 7 and 8, and 50 mmol/L carbonate-bicarbonate 
pH 10 and centrifuged (7 min, 25 °C, 16 100 rcf). We 
obtained partial elution at all pH values, with higher 
yields under more basic conditions (Fig. 11(a)). 
Figure 10 SDS-PAGE analysis of NIPAm/CB particles incubated with 
IL-8 diluted in Surine. Lane 1) IL-8 Control, Lane 2 NIPAm/CB particle 
supernatant (Out), Lane 3 NIPAm/CB particle content (In)
Figure 11  SDS PAGE analysis for optimizing the elution conditions. 
(a) Lane 1 hGH control; Lane 2 0.01 mg/mL hGH solution in Surine; 
Lane 3 NIPAm/CB particle content after elution at pH 7 (In); Lane 4 
NIPAm/CB particle content eluted at pH 7 (Eluate); Lane 5 NIPAm/CB 
particle content eluted at pH 7 (Eluate); Lane 6 NIPAm/CB particle 
content after elution at pH 8 (In); Lane 7 NIPAm/CB particle content 
eluted at pH 8 (Eluate); Lane 8 NIPAm/CB particle content eluted 
at pH 8 (Eluate); Lane 9 NIPAm/CB particle content after elution 
at pH 10 (In); Lane 10 NIPAm/CB particle content eluted at pH 10 
(Eluate); Lane 11 NIPAm/CB particle content eluted at pH 10 (Eluate). 
Partial elution of hGH from particles was obtained with buffers at 
pH 7, 8, and 10.  (b) Lane 1 hGH control; Lane 2 NIPAm/CB particle 
supernatant (Out); Lane 3 NIPAm/CB particle content after elution 
with acetonitrile/NH4HCO3(In); Lane 4 NIPAm/CB particle content 
eluted with acetonitrile/NH4HCO3 (Eluate); Lane 5 NIPAm/CB particle 
content eluted with acetonitrile/NH4HCO3(Eluate); Lane 6 NIPAm/
CB particle supernatant (Out); Lane 7 NIPAm/CB particle content 
after elution with acetonitrile/NH4OH (In); Lane 8 NIPAm/CB particle 
content eluted with acetonitrile/NH4OH (Eluate); Lane 9 NIPAm/CB 
particle content eluted with acetonitrile/NH4OH (Eluate). Complete 




In order to optimize the elution conditions, aliquots 
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Since our aim was complete retrieval of hGH 
from dye particles, we tested stronger elution buffers 
(50% acetonitrile (ACN) / 50 mmol/L NH4HCO3 and 
60% ACN/4% NH4OH). Based on the temperature 
dependence of particle size, we performed the elution 
for one hour at 38 ºC in order to diminish the volume 
of the particles and facilitate the elution of proteins 
(Fig. 11(b)). Complete elution was obtained by using 
60% ACN/4% NH4OH  buffer (Lanes 7, 8, and 9) 
while nearly complete elution was obtained with 50% 
ACN / 50 mmol/L NH4HCO3 (Lanes 3, 4, and 5).
2.8 Amplification of hGH concentration as 
measured by Immulite 1000 growth hormone 
system
The above data demonstrate that the NIPAm/CB 
nanoparticles were efficiently and rapidly able to 
capture and concentrate hGH dissolved at known 
concentrations in synthetic urine. In order to evaluate 
the concentration factor obtained using the particles 
as a trap, we used an immunometric assay, Immulite 
1000 Growth Hormone System. Immulite 1000 is 
a solid phase chemiluminescent immunometric 
assay platform, routinely used for the quantitative 
measurement of hGH in serum, whose linear range 
extends from 0.05 to 40 ng/mL. The estimated hGH 
concentration in a healthy individual’s urine is in 
the range of low pg/mL, which is lower than the 
detection limit of Immulite. Therefore, we tested the 
ability of nanoparticles to concentrate hGH from 
undetectable levels in model solutions. The goal 
was to raise the concentration of hGH into the linear 
range for detection by the Immulite assay.  
Surine is a model for urine that does not contain 
any protein. In order to better mimic real conditions, 
proteins were added to Surine at concentrations in 
the physiological range.  As previously discussed, CB 
has affi nity for a large class of proteins that, present 
in urine, could compete with hGH for the binding 
sites in the particles, reducing the efficiency of 
capture [42, 43].  In order to test the binding capacity 
of NIPAm/CB particles, we spiked recombinant 
hGH in 1 mL of Surine at pH 5, alone or in the 
presence of the following proteins: aprotinin (MW 
6.5 kDa), lysozyme (MW 14.4 kDa), BSA (MW 
66 kDa), trypsin inhibitor (21.5 kDa), and chemokine 
(C C motif) ligand 28, CCL28 (MW 14 kDa).  Each 
protein was dissolved in Surine at a concentration 
of 200 ng/mL, the total protein concentration was 
1 μg/mL, and the ratio of hGH to total protein 
in solution was 1 :10  000.  These solutions were 
incubated with 100 μL (570 μg) of NIPAm/CB 
particles. The incubation, washing and elution of 
particles was performed as previously described. Then, 
30 μL of Surine, supernatant and eluate were diluted 
1:10 in GH Sample Diluent, and hGH concentration 
was measured by Immulite assay.  As shown in Fig. 
12, hGH concentration in Surine in the absence of 
competitors was raised from 130 pg/mL to 2.93 ng/
mL, and hGH was not detectable in the supernatant. 
In presence of competing proteins, a starting hGH 
concentration of 60 pg/mL was measured in Surine, 
while hGH concentration in the eluate was 2.85 ng/
mL.  This demonstrates that the presence of potential 
protein competitors does not affect the efficiency of 
the particles in capturing hGH in solution.
Figure 12 Immulite assay readings for NIPAm/CB particles incubated 
with two different urine models containing hGH and Surine with and 
without interfering proteins. The effi ciency with which the particles 
concentrated hGH in Surine is not affected by the presence of 
proteins that may compete with the hormone for binding to the CB 
bait
Using a dose-saturation study, we evaluated the 
amount of particles required to collect all the hGH 
present in solution for a standard urine collection 
volume.  Aliquots of 1 mL of Surine containing 
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Figure 13 Particle dose response for capture of hGH. (a) 
Recombinant hGH was spiked in Surine and increasing amounts of 
particles were incubated with the analyte containing solution. The 
plateau is reached at about 600 µg. (b) Recombinant hGH was spiked 
in human urine and increasing amounts of particles were added to 
the solution. The plateau was reached at about 600 µg. (c) Cadaveric 




1 ng/mL of recombinant hGH were incubated 
with different aliquots of particles (20, 50, 100, 
200, 400 μL), corresponding to 114, 285, 570, 1140, 
and 2850 μg, respectively. Washing and elution of 
captured hGH analyte with 60% ACN/4% NH4OH 
were per formed as  descr ibed  above .  Equal 
volumes (30 μL) of Surine solution and of eluate 
from the particles were quantified by an Immulite 
1000 hGH assay. Samples were diluted 1:10 in GH 
Sample Diluent.  In Fig. 13(a), hGH concentration 
in the starting solution (0.08 ng/mL) is depicted by 
a horizontal line; the plateau was reached with an 
incubation of 570 μg of particles. The same saturation 
study was performed with recombinant hGH spiked 
in human urine and cadaveric hGH spiked in human 
urine. The total protein concentration of human urine 
was 37.9 μg/mL ± 6.67 μg/mL, as measured by the 
Bradford Assay.  The results are reported in Fig. 13(b) 
and Fig. 13(c), respectively. Notably, the particles 
were able to capture recombinant and cadaveric hGH 
spiked in human urine, showing that no interference 
was caused by the presence of proteins or any other 
physiological constituent of urine. 
Further studies were performed to better 
understand the amplification power of the NIPAm/CB 
particles. Appropriate amounts of hGH were 
dissolved in separate samples of Surine to give 
concentrations of < 0.05 ng/mL and concentration of 
0.3 μg/mL. Aliquots of 1 mL of each solution were 
incubated with 100 μL (570 μg) of particles. As shown 
in Fig. 14, when starting from an undetectable hGH 
concentration (< 0.05 ng/mL), Immulite readings of 
hGH eluted from the particles gave a value of 2.0 ng/
mL. When starting from a 0.3 ng/mL hGH solution, 
the concentration of hGH in the particle eluate was 
brought into the linear range of the Immulite assay. 
In an attempt to mimic conditions more relevant 
to clinical settings, incubations of an initial volume of 
Surine of 10 mL were performed with 1 mL (5.7 mg) 
of particles. The volume ratio between the starting 
urine solution and the particle eluate was 10 mL 
÷ 0.15 mL = 67; therefore the expected maximum 
amplifi cation factor was 67. When recombinant hGH 
was spiked at a concentration below the detection 
limit of the Immulite assay (<0.05 ng/mL) the 
particle sequestration increased the concentration to 
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Cmin = T / (V/v) = T / c,
where Cmin is the minimum detectable concentration 
of hGH in urine, T is the lowest limit of sensitivity of 
the immunoassay, V is the starting volume of urine 
tested, v is the output volume of the eluate, and 
c=V/v is the concentration factor given by the ratio 
between the initial volume of urine and the volume 
of the eluate. Assuming that we have 100 mL of urine 
and the protein analytes captured in the particles can 
be eluted in the volume v of 200 μL, the concentration 
factor c is 500 and the sensitivity of the immunoassay 
T is 50 pg/mL; in this case Cmin , the minimum 
detectable concentration of hGH, will be 0.1 pg/mL 
with the immunoassay used in this study and with 
100 mL of urine as a starting volume. 
In order to test the ability of NIPAm/CB particles 
to collect and concentrate the endogenous hGH in 
human urine, we collected blood and urine from a 
healthy donor and tested both body fluids for hGH 
content. The hGH value in the blood was 1.34 ng/mL, 
while the urine hGH value was below the detection 
limit of the Immulite assay (<0.05 ng/mL).  NIPAm/
Figure 14 Effective amplification of urine hGH immunoassy 
sensitivity. Particles raised the concentration of recombinant hGH 
above the detection limit of the Immulite and greatly amplified 
the concentration of a solution in the linear range. UD means 
undetectable (below the detection limits of the Immulite assay)
a value of 1.21 ng/mL. When the initial concentration 
in Surine was 170 pg/mL, the concentration of 
hGH measured in the particle eluate was 6.50 ng/mL 
(concentration factor=38). Starting from an initial 
hGH concentration in Surine of 800 pg/mL, the 
concentration measured by the Immulite assay 
exceeded the upper detection limit (40 ng/mL) of 
the assay (Fig. 15) (indicating a concentration factor 
greater than 50). All the supernatant fractions were 
completely depleted of hGH; this demonstrated that 
the particles captured all of the solution phase hGH 
in the entire volume of sample. As an additional 
quality check, the concentration of hGH in the 
particle eluate was found to be linearly dependent on 
the concentration of hGH in the starting solution of 
Surine, with coeffi cients of variation less than 5%.
These data demonstrate that NIPAm/CB particles 
sequestered and concentrated hGH, a very low 
abundance biomarker in urine, raising the effective 
sensitivity from below the detection limit of a clinical 
immunoassay well into the linear range of the 
assay. A simple mathematical equation can predict 
the minimum concentration of hGH detectable by 
immunoassay following particle-based concentration 
and elution, knowing the sensitivity of the assay, the 
initial volume of urine, and the output volume of the 
elution:  
Figure 15 Effective amplification of urine hGH immunoassy 
sensitivity. Dose response study on recombinant hGH spiked in 10 ml 
of Surine. Supernatants are depleted and hGH concentration in the 
particle eluate is linearly dependent on hGH concentration in Surine. 
UD means undetectable (below the detection limits of the Immulite 
assay)
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CB particles (3 mL, 17.1 mg) were incubated with 33 
mL of urine (pH 6.5) and processed as previously 
described. Particle eluate (100 μL) was diluted 1:2 
with Sample Diluent and analyzed by Immulite 
assay. The hGH concentration in the particle eluate 
was 0.058 ng/mL. We can therefore estimate the 
initial concentration of hGH in urine as 58 pg/mL/ 
(33 mL ÷ 0.1 mL) = 58 pg/mL ÷ 330 = 0.175 pg/mL.
3. Conclusions
The ability to obtain a quantitative measurement of 
low molecular weight and low abundance proteins in 
human urine has important implications for clinical 
diagnosis and research, since many disease-related 
markers are low molecular weight peptides, proteins 
and metabolites that pass effectively through kidney 
glomerular fi ltration.  
The normal range of hGH in serum is 1 to 10 
ng/mL but the urine concentration is around a 
thousand times lower, well below the detection 
limit (50 pg/mL) of most commercially available 
sensitive clinical hGH immunoassays. We have 
recently described the application of hydrogel 
nanoparticles for rapid biomarker concentration 
in blood [16]. In the present study we developed a 
new class of Cibacron Blue nanoparticles tailored 
for urine-based applications and used hGH as 
an example of a very low abundant biomarker 
whose routine urine measurement remains elusive 
because of its low concentration. 
We synthesized Cibacron Blue bait-loaded 
hydrogel particles and successfully demonstrated 
their ability to capture, concentrate and preserve 
both recombinant and natural (cadaveric) hGH 
from model synthetic urine solutions, and from 
actual human urine. The optimized elution method 
we developed, based on strong base-containing 
buffers, was totally compatible with clinical grade 
immunological assays. The amount of hGH eluted 
from the particles was successfully measured by 
Immulite 1000 assay, which is routinely used for 
clinical serum analysis. Originally undetectable 
concentrations of hGH (below 0.05 ng/mL) in a standard 
assay volume were dramatically increased, reaching 
a reliable detectable concentration (2.0 ng/mL). 
These findings suggest that hydrogel particles 
functionalized with Cibacron Blue dye constitute 
a promising technology for the pre-processing of 
hGH in urine prior to its measurement by means of 
standard immunological techniques routinely used 
in clinical settings. The sensitivity in the linear range 
of a standard clinical assay for 100 mL of urine is 0.1 
pg/mL. The physiological levels of hGH in human 
urine are poorly understood because it has not been 
readily possible to measure this analyte in the urine. 
In this study, urine from a healthy donor whose 
serum hGH concentration was 1.34 ng/mL was 
studied in order detect endogenous hGH. Starting 
from a volume of 33 mL, the particle eluate had an 
hGH concentration of 58 pg/mL, giving an estimated 
initial concentration of hGH in the urine of 0.175 pg/mL. 
The binding ability of the NIPAm/CB particles is 
not restricted to hGH; indeed we demonstrated that 
IL-8, a potential disease biomarker found in urine and 
blood, was successfully captured and concentrated 
by the particles. Hydrogel particles are highly stable 
in either dried or hydrated states. Thus, it would be 
feasible to preload the particles into a urine collection 
vessel so that clinically relevant small proteins could 
be immediately sequestered and preserved from the 
entire volume of collected urine and made available 
for analysis by clinical grade immunoassays. The 
nanotechnology described here appears to have 
the desired precision, accuracy, and sensitivity to 
support a large scale clinical study of urine candidate 
biomarkers.
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